Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Big Data: Moving From Artificial Trials To A Smarter Regulatory Process

Executive Summary

This year the EU Big Data Task Force intends to deliver an EU-wide strategy on how big data can be used to support the development and evaluation of new medicines. The recent massive growth of data generated by various technologies, such as ‘omics, portable devices, the internet of things and even social media, gives this task force an urgency for pharma and regulators. Bruno Boulanger discusses the impact this will have on how the pharmaceutical industry gathers and delivers data in the future.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

PS123109

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel